Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kyle Blair

Retina Specialist Des Plaines, IL Medical Doctor

NPI 1699121194 CMS profile 11309942

2454 E Dempster St Ste 400, Des Plaines, IL 60016

Open in the dashboard

General payments

$4,963

45 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kyle Blair of Des Plaines, IL is reported in the CMS Open Payments database as having received $4,963 across 45 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Retina Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $147 5
2022 General $3,047 20
2021 General $1,769 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kyle Blair
  • Retina Specialist median
  • Middle half of Retina Specialist
  • National median

In program year 2025, general payments to Kyle Blair were reported at $147. Among 1,235 Retina Specialist profiles paid that year, the median was $457 and the middle half received between $175 and $1,079.

Show as a table
Year Kyle Blair Retina Specialist median Middle half National median
2019 $0 $410 $157–$1,517 $163
2020 $0 $168 $65–$778 $114
2021 $1,769 $258 $101–$1,161 $132
2022 $3,047 $418 $162–$1,488 $149
2023 $0 $476 $178–$1,312 $160
2024 $0 $520 $188–$1,372 $164
2025 $147 $457 $175–$1,079 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Bausch & Lomb, a division of Bausch Health US, LLC $1,769 20 payments
  2. Bausch & Lomb Americas Inc. $1,675 16 payments
  3. Alcon Vision LLC $1,295 4 payments
  4. Regeneron Healthcare Solutions, Inc. $135 2 payments
  5. Astellas Pharma US Inc $30 1 payment
  6. Apellis Pharmaceuticals, Inc. $30 1 payment
  7. ANI Pharmaceuticals, Inc. $28 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $3,457 16 payments
  2. Food and Beverage $1,506 29 payments
Products named General payments · program years 2021–2025
  1. Crystalens Accommodating IOL (AT-52AO) $1,769 20 payments
  2. Akreos AO IOL $1,769 20 payments
  3. Trulign IOL $1,769 20 payments
  4. enVista MX60 IOL $1,769 20 payments
  5. STELLARIS Ophthalmology $1,769 20 payments
  6. STELLARIS Ophthalmology $1,652 15 payments
  7. OPHTHALMIC INSTRUMENTS $1,652 15 payments
  8. EYLEA $100 1 payment
  9. EYLEA HD $35 1 payment
  10. Izervay $30 1 payment
  11. Other $81 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

329

Median for Ophthalmology: 891

Drug cost

$5,773

Median for Ophthalmology: $68,233

Branded share of claims

19.1%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 105 $3,255
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 63 $1,080
Ketorolac Tromethamine Generic 56 $693
Brimonidine Tartrate Generic 49 $372
Latanoprost Generic 28 $224
Timolol Maleate Generic 28 $151

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$1,608,152

Of which drugs: $1,289,056

Medicare patients

850

Average age 77

Services billed

15,173

483 women, 367 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 38%
Chronic kidney disease 30%
Ischemic heart disease 27%
Atrial fibrillation 20%
Heart failure 19%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 189 1,244 $815,292
Injection, faricimab-svoa, 0.1 mg J2777 Office 36 8,280 $224,925
Injection, aflibercept hd, 1 mg J0177 Office 24 576 $152,320
Injection, bevacizumab, 10 mg J9035 Office 71 154 $8,734

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

45 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Retina Specialist in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record